Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Operating Expenses (2016 - 2019)

Historic Other Operating Expenses for Northwest Biotherapeutics (NWBO) over the last 10 years, with Q4 2019 value amounting to -$3.3 million.

  • Northwest Biotherapeutics' Other Operating Expenses fell 82656.25% to -$3.3 million in Q4 2019 from the same period last year, while for Sep 2020 it was -$3.3 million, marking a year-over-year decrease of 18790.17%. This contributed to the annual value of $4.5 million for FY2018, which is 5018.25% down from last year.
  • Northwest Biotherapeutics' Other Operating Expenses amounted to -$3.3 million in Q4 2019, which was down 82656.25% from $802000.0 recorded in Q3 2019.
  • Over the past 5 years, Northwest Biotherapeutics' Other Operating Expenses peaked at $6.6 million during Q4 2015, and registered a low of -$3.3 million during Q4 2019.
  • For the 5-year period, Northwest Biotherapeutics' Other Operating Expenses averaged around $1.6 million, with its median value being $1.5 million (2017).
  • As far as peak fluctuations go, Northwest Biotherapeutics' Other Operating Expenses soared by 3143333.33% in 2016, and later plummeted by 82656.25% in 2019.
  • Over the past 5 years, Northwest Biotherapeutics' Other Operating Expenses (Quarter) stood at $6.6 million in 2015, then tumbled by 76.48% to $1.5 million in 2016, then fell by 2.33% to $1.5 million in 2017, then plummeted by 70.35% to $448000.0 in 2018, then plummeted by 826.56% to -$3.3 million in 2019.
  • Its Other Operating Expenses was -$3.3 million in Q4 2019, compared to $802000.0 in Q3 2019 and $914000.0 in Q2 2019.